DR. EDWARD D BALL, M.D.
Osteopathic Medicine at Arbor Dr, San Diego, CA
License number
California G84752
Category
Osteopathic Medicine
Type
Internal Medicine
License number
California G84752
Category
Osteopathic Medicine
Type
Hematology
License number
California G84752
Category
Osteopathic Medicine
Type
Medical Oncology
Address
Address
200 W Arbor Dr, San Diego, CA 92103
Phone
(858) 822-6842
Personal information
See more information about EDWARD D BALL at radaris.comName
Address
Phone
4678 W Hoffer St, Banning, CA 92220
6219 County Road 14, Orland, CA 95963
6265 Caminito Luisito, San Diego, CA 92111
525 E Seaside Way UNIT 1602, Long Beach, CA 90802
10227 Los Ranchitos Rd, Lakeside, CA 92040
Professional information
Dr. Edward D Ball, La Jolla CA - MD (Doctor of Medicine)
Specialties:
Hematology, Medical Oncology, Oncology
Address:
UCSD Morris Cancer Center
3855 Health Sciences Dr SUITE 1102, La Jolla 92093
(858) 822-6100 (Phone)
200 W Arbor Dr, San Diego 92103
(858) 822-6842 (Phone)
3855 Health Sciences Dr SUITE 1102, La Jolla 92093
(858) 822-6100 (Phone)
200 W Arbor Dr, San Diego 92103
(858) 822-6842 (Phone)
Certifications:
Hematology, 2000, Internal Medicine, 1979, Medical Oncology, 1983
Awards:
Healthgrades Honor Roll
Languages:
English, Chinese, Russian, Spanish
Education:
Medical School
Case Western Reserve University School Of Medicine
Graduated: 1976
Hartford Hospital
Mary Hitchcock Mem Hospital
University Hospitals Of Cleveland
Case Western Reserve University School Of Medicine
Graduated: 1976
Hartford Hospital
Mary Hitchcock Mem Hospital
University Hospitals Of Cleveland
Monoclonal Antibody And Antigens Specific Therefor And Methods Of Using Same
US Patent:
6340569, Jan 22, 2002
Filed:
Nov 12, 1998
Appl. No.:
09/189926
Inventors:
Edward D. Ball - San Diego CA
Rui-Kun Zhong - San Diego CA
Rui-Kun Zhong - San Diego CA
Assignee:
University of Pittsburgh - Pittsburgh PA
International Classification:
G01N 3353
US Classification:
435 72, 435 29, 435325, 435326, 4353722, 5303887, 53038873
Abstract:
Disclosed herein are hybridomas, antibodies produced thereby, antigens, and cells identified or isolated therewith. The dendritic like cells preferably have dendritic morphology and B cell phenotype. Methods of utilizing the hybridomas, antibodies, antigens, and cells are also discussed herein.
Method Of Increasing Efficacy Of Tumor Cell Killing Using Combinations Of Anti-Neoplastic Agents
US Patent:
7977320, Jul 12, 2011
Filed:
Oct 28, 2005
Appl. No.:
11/718127
Inventors:
Edward D. Ball - San Diego CA, US
Larissa Balaian - San Diego CA, US
Larissa Balaian - San Diego CA, US
Assignee:
The Regents of the University of California - Oakland CA
International Classification:
A01N 43/04, A61K 31/70
US Classification:
514 43, 514 42, 514 49, 514 45
Abstract:
The present invention provides compositions and methods for increasing the amount of active Syk protein kinase and or SHP-1 protein phosphatase in a cell. The compositions and methods are useful for increasing the efficacy of anti-neoplastic agents, such as those that target the CD33 protein, and which are used to treat leukemia. The invention thus provides for treatment of cancers, including leukemias. The invention also provides screening assays for anti-neoplastic agents in vitro. Methods of screening patients for responsiveness to anti-CD33 treatments are also provided.